Skip to content

Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG (EPEGE)

Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00502190
Acronym
EPEGE
Enrollment
220
Registered
2007-07-17
Start date
2007-06-30
Completion date
2011-06-30
Last updated
2011-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Twin Pregnancy

Keywords

pessary, extending pregnancy

Brief summary

Randomized, opened multicentric study evaluating the Effectiveness of Pessary in the patients with a Gemellary pregnancy and a collar runs between 20 and 28 weeks of amenorrhoea

Detailed description

Randomized, opened multicentric study evaluating the Effectiveness of Pessary in the patients with a Gemellary pregnancy and a collar runs between 20 and 28 weeks of amenorrhoea To show that the use of pessary makes it possible to lengthen the duration of the pregnancy of at least 10 days in patients with a twin pregnancy and a uterine collar length \< = 25 mm measured by echography between 20 and 28 SA compared to the group controls.

Interventions

DEVICESilicon ring positioned in the vagina, around the cervix

Silicon ring positioned in the vagina, around the cervix

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years (legal majority in France) * Inclusion pessary positioning before 28 WG * Twin pregnancies, mono or dichorionic, diamniotic * Transvaginal cervical length ( 25mm between 20 et 28 WG * Intact membranes * No signs of infection (negative urine culture, CRP \<10mg/l , blood white cell count \<15000/ml) * Patient accepting follow-up * Covered by health insurance for France

Exclusion criteria

* Cerclage * No more cervix * Chorioamnionitis * Abnormal CTG * Placenta praevia * Abruptio * Bleeding * PROM * Singleton or multiple \>2 * Monochorionic monoamniotic twin pregnancy * IUGR * Preeclampsia or other PIH * TTTS * Uncontrolled diabetes * Other maternal of fetal pathology responsible for preterm deliveries * Patient included in other therapeutic trials * Patient without legal freedom to consent * Homeless or no fixed address

Design outcomes

Primary

MeasureTime frameDescription
Demonstrate the profit of 10 days in the pessary group compared to control.at least 10 daysDemonstrate the profit of 10 days in the pessary group compared to control

Secondary

MeasureTime frameDescription
To evaluate and compare the frequency of the childbirth < 34 SAbefore 34 weeks
Deliveries (<34WG)34 weeksDeliveries (\<34WG)
Evaluate the rate of side effects of pessariesduring the pessariesEvaluate the rate of side effects of pessaries
Neonatal outcomebefore 28 weeksNeonatal outcome

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026